Results 161 to 170 of about 131,340 (225)

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

open access: yesBJU International, Volume 138, Issue 4, Page 607-619, October 2026.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan   +13 more
wiley   +1 more source

Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study. [PDF]

open access: yesRheumatol Int
Drougkas K   +12 more
europepmc   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

open access: yesJournal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Hereditary nephritis

open access: yes, 1990
International Meeting on Recent Advances in Hereditary Nephritis 1989 Vimercate   +1 more
core  

Home - About - Disclaimer - Privacy